Koshinski Asset Management Inc. Has $263,000 Holdings in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)

Koshinski Asset Management Inc. raised its position in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) by 10.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,077 shares of the exchange traded fund’s stock after purchasing an additional 490 shares during the quarter. Koshinski Asset Management Inc. owned approximately 0.12% of ProShares Ultra Nasdaq Biotechnology worth $263,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BIB. Bell Rock Capital LLC raised its holdings in ProShares Ultra Nasdaq Biotechnology by 30.8% in the 1st quarter. Bell Rock Capital LLC now owns 21,530 shares of the exchange traded fund’s stock valued at $1,197,000 after acquiring an additional 5,075 shares in the last quarter. Capital Investment Advisors LLC raised its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 5.0% in the 2nd quarter. Capital Investment Advisors LLC now owns 9,645 shares of the exchange traded fund’s stock worth $500,000 after buying an additional 455 shares in the last quarter. Toth Financial Advisory Corp grew its position in ProShares Ultra Nasdaq Biotechnology by 6.4% during the 1st quarter. Toth Financial Advisory Corp now owns 9,501 shares of the exchange traded fund’s stock worth $527,000 after acquiring an additional 575 shares during the last quarter. Moors & Cabot Inc. bought a new stake in ProShares Ultra Nasdaq Biotechnology during the 2nd quarter worth approximately $207,000. Finally, Truvestments Capital LLC bought a new stake in ProShares Ultra Nasdaq Biotechnology during the 1st quarter worth approximately $42,000.

Shares of BIB opened at $45.69 on Friday. The business’s fifty day moving average price is $48.99 and its two-hundred day moving average price is $51.14. ProShares Ultra Nasdaq Biotechnology has a 52 week low of $36.05 and a 52 week high of $70.82.

ProShares Ultra Nasdaq Biotechnology Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Further Reading: Equity Income

Institutional Ownership by Quarter for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.